Trade

with

Amarin Corp PLC
(NASDAQ: AMRN)
AdChoices
=
1.05
0.00
0.00%
After Hours :
1.05
0.00
0.00%

Open

1.03

Previous Close

1.05

Volume (Avg)

807.84k (2.76M)

Day's Range

1.01-1.07

52Wk Range

0.9400-2.75

Market Cap.

183.33M

Dividend Rate ( Yield )

-

Beta

0.92

Shares Outstanding

174.60M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 26.35M

    • Net Income

    • -166.23M

    • Market Cap.

    • 183.33M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -178.11

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.92

    • Forward P/E

    • -2.80

    • Price/Sales

    • 4.38

    • Price/Book Value

    • -3.67

    • Price/Cash flow

    • -1.58

      • EBITDA

      • -134.35M

      • Return on Capital %

      • -35.65

      • Return on Equity %

      • -

      • Return on Assets %

      • -35.65

      • Book Value/Share

      • -0.29

      • Shares Outstanding

      • 174.60M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Hold
        • 1 Year Price Target

        • 2.25

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.41

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 129.20

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 59.48

            • 64.72

            • Pre-Tax Margin

            • -176.13

            • 13.77

            • Net Profit Margin

            • -178.11

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 4.69

              • 1.52

              • Quick Ratio

              • 4.14

              • 0.87

              • Interest Coverage

              • -2.02

              • 6.77

              • Leverage Ratio

              • -

              • 1.91

              • Book Value/Share

              • -0.29

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.41

                • 63.29

                • P/E Ratio 5-Year High

                • -45.65

                • 237.47

                • P/E Ratio 5-Year Low

                • -2.14

                • 19.71

                • Price/Sales Ratio

                • 4.38

                • 3.53

                • Price/Book Value

                • -3.67

                • 3.31

                • Price/Cash Flow Ratio

                • -1.58

                • 21.23

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -35.65

                    (-179.90)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 0.75

                  • 1.80

                  • Asset Turnover

                  • 0.20

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -182.11M
                  Operating Margin
                  -691.08
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.58
                  Ownership

                  Institutional Ownership

                  31.59%

                  Top 10 Institutions

                  22.25%

                  Mutual Fund Ownership

                  5.95%

                  Float

                  -

                  5% / Insider Ownership

                  0.27%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • iShares Nasdaq Biotechnology

                  •  

                    2,211,797

                  • 3.08

                  • 1.22

                  • Franklin Biotechnology Discovery

                  •  

                    2,157,300

                  • 0.00

                  • 1.25

                  • Franklin Biotechnology Discovery Fund

                  •  

                    1,457,900

                  • 0.00

                  • 0.84

                  • Columbia Overseas Value Fund

                  •  

                    1,064,484

                  • -8.12

                  • 0.61

                  • AB SICAV International Health Care

                  •  

                    767,630

                  • 0.00

                  • 0.44

                  • Columbia International Value Fund

                  •  

                    319,596

                  • -8.76

                  • 0.18

                  • Turner Medical Sciences Long/Short

                  •  

                    309,470

                  • -2.80

                  • 0.18

                  • Fidelity Advisor® Growth Opportunities

                  •  

                    265,000

                  • 0.00

                  • 0.15

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Camber Capital Management LLC

                  •  

                    11,000,000

                  • 0.00%

                  • 6.36

                  • Abingworth LLP

                  •  

                    8,087,486

                  • 0.00%

                  • 4.65

                  • Oracle Investment Management Inc

                  •  

                    3,700,000

                  • +23.33%

                  • 2.14

                  • Franklin Advisers, Inc.

                  •  

                    3,615,200

                  • 0.00%

                  • 2.09

                  • Visium Asset Management LLC

                  •  

                    3,101,182

                  • -4.20%

                  • 1.79

                  • Columbia Mangmt Investment Advisers, LLC

                  •  

                    2,512,803

                  • -2.09%

                  • 1.45

                  • Adage Capital Partners Gp LLC

                  •  

                    2,000,000

                  • 0.00%

                  • 1.16

                  • BlackRock Fund Advisors

                  •  

                    1,960,744

                  • -2.96%

                  • 1.13

                  • D. E. Shaw & Co LP

                  •  

                    1,192,282

                  • +1,158.58%

                  • 0.69

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Slow Growth

                  Style

                  -

                  Amarin Corp PLC formerly Ethical Holdings plc is a public limited company incorporated under the laws of England and Wales. It was originally incorporated in England as a private limited company on March 1, 1989 under the Companies A...morect 1985, and re-registered in England as a public limited company on March 19, 1993. The Company is a biopharmaceutical company having expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company’s product Vascepa® (icosapent ethyl) capsules is approved by the U.S. Food and Drug Administration for the use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG>500mg/dL) hypertriglyceridemia. On January 28, 2013 the Company commenced full commercial launch of Vascepa...more. The Company refers to its second indication for Vascepa as the ANCHOR indication. The FDA views the proposed ANCHOR indication as ostensibly and impliedly an indication to reduce cardiovascular risk. In addition, in December 2011, the Company announced commencement of patient dosing in cardiovascular outcomes study of Vascepa, titled REDUCE-IT or Reduction of Cardiovascular Events with EPA—Intervention Trial. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing cardiovascular events in a high risk patient population on statin therapy. The Company has over 6,500 patients enrolled in the REDUCE-IT study. The Company has pending supplemental new drug application, with the FDA that seeks marketing approval of Vascepa for use in the ANCHOR indication. Vascepa became commercially available in the United States by prescription in early 2013. On January 28, 2013, the Company commenced full commercial launch of Vascepa in the United States for use in the MARINE indication. The Company now markets Vascepa in the United States through sales force of approximately 150 sales professionals and also employed marketing and medical affairs personnel to support commercialization of Vascepa. As of February 1, 2014, over 16,000 clinicians had written prescriptions for Vascepa. In November 2010, the Company reported top-line data for the MARINE trial. Vascepa was well tolerated in the MARINE trial, with a safety profile comparable to placebo and there were no treatment-related serious adverse events observed. No significant changes in fasting blood glucose, hemoglobin A1C, vital signs, electrocardiograms, or liver or kidney function were observed with either Vascepa dose. The Company uses third party manufacturers and suppliers to manufacture clinical and commercial quantities of ethyl-EPA, which constitutes the only active pharmaceutical ingredient within Vascepa, to encapsulate, bottle and package Vascepa and to maintain inventory of Vascepa. The Company currently relies on Patheon for the encapsulation of Vascepa. The Companies competitors include GlaxoSmithKline plc and AbbVie, Inc., and Niaspan. The Company is subject to regulation by government authorities, including FDA.lessless

                  Key People

                  John F. Thero

                  CEO/Director/President

                  Dr. Lars Ekman M.D.,PhD

                  Chairman of the Board

                  Michael Farrell

                  CFO/Chief Accounting Officer/Controller

                  Dr. James I. Healy

                  Director

                  David M. Stack

                  Director

                  • Amarin Corp PLC

                  • 2 Pembroke House

                  • Dublin, 2

                  • GBR.Map

                  • Phone: +353 16699020

                  • Fax: -

                  • amarincorp.com

                  Incorporated

                  1989

                  Employees

                  185

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: